Skip to main content

Table 2 Results of univariate and multivariate analyses

From: Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols-

Factor 5-year OS rate (%) (95 % CI) UA (p value) MA (p value)
Age at radiotherapy   0.393 0.162
 66 years or less 47.2 (38.7–55.9)   
 More than 66 years 39.4 (30.5–49.1)   
Gender   0.100 0.215
 Male 41.2 (34.6–48.1)   
 Female 58.1 (40.8–73.7)   
Performance status   0.008 0.655
 0 48.7 (33.1–64.6)   
 1 44.3 (36.7–52.1)   
 2 22.3 (9.5–44.1)   
Primary site   0.714 0.810
 Upper thoracic esophagus 38.9 (24.4–55.7)   
 Middle thoracic esophagus 42.9 (34.4–51.9)   
 Lower thoracic esophagus 46.6 (35.7–57.8)   
Stage   <0.001 <0.001
 II 64.0 (52.5–74.2)   
 III (non-T4) 40.1 (31.0–49.9)   
 III (T4) 22.5 (13.7–35.5)   
Protocol   0.082 0.043
 Group A 52.4 (35.0–69.3)   
 Group B 45.2 (37.0–53.6)   
 Group C 37.2 (26.8–48.8)   
Radiotherapy dose   0.090 0.973
 60 Gy or less 46.0 (28.1–51.2)   
 More than 60 Gy 39.1 (38.7–53.5)   
Concomitant chemotherapy   <0.001 <0.001
 1 cycle 27.9 (14.5–46.9)   
 2 cycles 46.0 (39.3–52.8)   
Adjuvant chemotherapy   0.885 0.306
 With 45.1 (38.1–52.5)   
 Without 38.8 (26.8–52.3)   
  1. OS overall survival, CI confidence interval, UA univariate analysis, MA multivariate analysis